Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG. [electronic resource]
Producer: 20120807Description: 998-1008 p. digitalISSN:- 1095-8584
- 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester -- pharmacology
- Action Potentials
- Arrhythmias, Cardiac -- drug therapy
- Benzazepines -- pharmacology
- Calcium Channel Agonists -- pharmacology
- Calcium Channel Blockers -- pharmacology
- Calcium Signaling
- Cells, Cultured
- Cisapride -- pharmacology
- Drug Evaluation, Preclinical
- ERG1 Potassium Channel
- Embryonic Stem Cells -- physiology
- Ether-A-Go-Go Potassium Channels -- antagonists & inhibitors
- Humans
- Myocytes, Cardiac -- drug effects
- Nifedipine -- pharmacology
- Patch-Clamp Techniques
- Sodium Channels -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.